US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Anti-Pandemic Concept

1,327.58

-9.1315-0.68%

Number of Gainers:5

Number of Losers:15

Number of Flat:- -

PE:- -

High:1,343.21

Open:1,342.69

Low:1,326.57

Close:1,336.71

Loading ...

Moderna (MRNA) Gets a Hold from TD Cowen

BioNTech Se : Citigroup Cuts Target Price to $140 From $145

THOMSON REUTERS

BioNTech price target lowered to $140 from $145 at Citi

BioNTech SE Reports Q1 2025 Financial Results

Health Care Down on Mixed Earnings -- Health Care Roundup

Press Release: Viatris Announces Appointments of Frank D'Amelio and Michael Severino, M.D., to the Company's Board of Directors

BioNTech Appoints Novartis Executive As Finance Chief, Reaffirms 2025 Outlook Focusing on Oncology Expansion

Optimism is Back for Biotech Stocks. This Time, It Could Last. -- Barrons.com

BioNTech price target lowered to $127 from $143 at BofA

Sector Update: Health Care Stocks Lower Monday Afternoon

MT Newswires Live

Analysts Offer Insights on Healthcare Companies: BioNTech SE (BNTX), PTC Therapeutics (PTCT) and Larimar Therapeutics (LRMR)

Narrower Guidelines for Covid-19 Booster Wouldn't Limit BioNTech's Customer Base Much -- Market Talk

European Equities Traded in the US as American Depositary Receipts Marginally Higher in Monday Trading

MT Newswires Live

India Offers US Reciprocal Zero Tariffs on Steel, Auto Parts, Pharmaceutical Drugs, Bloomberg Reports

MT Newswires Live

Why Gilead Sciences (GILD) is a Top Value Stock for the Long-Term

BRIEF-Novavax To Receive $19.5 Million Upfront Payment Under Amended Agreement With Takeda

Novavax - to Receive $19.5 Mln Upfront Payment Under Amended Agreement With Takeda - SEC Filing

THOMSON REUTERS

Johnson & Johnson Says New Data Show Tremfya's Sustained Efficacy in Ulcerative Colitis

MT Newswires Live

Novavax Updates Financial Terms With Takeda for Covid-19 Vaccine Agreement in Japan

MT Newswires Live

BRIEF-Novavax Announces Improved Terms For Collaboration, License Agreement With Takeda For Nuvaxovid In Japan

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/BK4568/news?page=5"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK4568","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4568\",,,,,undefined,":{"symbol":"BK4568","market":"US","secType":"PLATE","nameCN":"Anti-Pandemic Concept","latestPrice":1327.5806,"timestamp":1746820799999,"preClose":1336.712,"halted":0,"volume":113582454,"delay":0,"changeRate":-0.006831,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Market Closed","change":-9.13147,"latestTime":"05-09 16:00:00 EDT","open":1342.69,"high":1343.2052,"low":1326.5701,"amount":4653162209.902576,"amplitude":0.012445,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1747036800000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"pbRate":3.565313,"peRate":21.186942,"turnoverRate":0.007317,"increases":5,"decrements":15,"flats":0,"marketCap":1093969830401.5,"floatMarketCap":1075897192963},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4568\",,,,,undefined,":{"symbol":"BK4568","high":1343.2052,"amplitude":0.012445,"preClose":1336.712,"low":1326.5701,"pbRate":"3.565313","latestPrice":1327.5806,"volume":113582454,"delay":0,"open":1342.69,"prevYearClose":1274.8187,"prevWeekClose":1375.2667,"prevMonthClose":1374.5028,"prevQuarterClose":1427.887,"fiveDayClose":1375.2667,"twentyDayClose":1281.7616,"sixtyDayClose":1380.7908,"secType":"PLATE","market":"US","turnoverRate":0.007317,"peRate":21.186942,"marketCap":1093969830401.5,"floatMarketCap":1075897192963,"timestamp":1746820799999,"nameCN":"Anti-Pandemic Concept"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK4568\",,,,undefined,":{"bkCode":"BK4568","up":5,"down":15,"flat":0},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK4568\",pageSize:20,pageCount:5,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2533768724","title":"Moderna (MRNA) Gets a Hold from TD Cowen","url":"https://stock-news.laohu8.com/highlight/detail?id=2533768724","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533768724?lang=en_us&edition=fundamental","pubTime":"2025-05-06 19:56","pubTimestamp":1746532611,"startTime":"0","endTime":"0","summary":"TD Cowen analyst Tyler Van Buren maintained a Hold rating on Moderna (MRNA – Research Report) today and set a price target of $30.00. The company’s...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/moderna-mrna-gets-a-hold-from-td-cowen?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/moderna-mrna-gets-a-hold-from-td-cowen?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4533","BK4548","BK4207","BK4501","BK4551","COWN","TD","BK4127","BK4534","BK4568","BK4532","BK4588","BK4139","BK4566","MRNA","BK4585"],"gpt_icon":0},{"id":"2533507546","title":"BioNTech Se : Citigroup Cuts Target Price to $140 From $145","url":"https://stock-news.laohu8.com/highlight/detail?id=2533507546","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533507546?lang=en_us&edition=fundamental","pubTime":"2025-05-06 18:22","pubTimestamp":1746526958,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250506:nFWN3RE16K:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BNTX","BK4139","BK4568","BK4588","BK4535","BK4548","BK4551","BK4585"],"gpt_icon":0},{"id":"2533850486","title":"BioNTech price target lowered to $140 from $145 at Citi","url":"https://stock-news.laohu8.com/highlight/detail?id=2533850486","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533850486?lang=en_us&edition=fundamental","pubTime":"2025-05-06 17:50","pubTimestamp":1746525046,"startTime":"0","endTime":"0","summary":"Citi lowered the firm’s price target on BioNTech (BNTX) to $140 from $145 and keeps a Buy rating on the shares following the Q1 report. The quarter...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/biontech-price-target-lowered-to-140-from-145-at-citi?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/biontech-price-target-lowered-to-140-from-145-at-citi?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4585","BK4568","BK4551","BK4588","BNTX","BK4535","BK4139","BK4548"],"gpt_icon":0},{"id":"2533545996","title":"BioNTech SE Reports Q1 2025 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2533545996","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533545996?lang=en_us&edition=fundamental","pubTime":"2025-05-06 12:04","pubTimestamp":1746504267,"startTime":"0","endTime":"0","summary":"Biontech Se Sponsored Adr ( ($BNTX) ) has released its Q1 earnings. Here is a breakdown of the information Biontech Se Sponsored Adr presented to i...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/biontech-se-reports-q1-2025-financial-results-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/biontech-se-reports-q1-2025-financial-results-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BK4551","BK4535","BK4588","BNTX","BK4548","BK4568","BK4585"],"gpt_icon":0},{"id":"2533856130","title":"Health Care Down on Mixed Earnings -- Health Care Roundup","url":"https://stock-news.laohu8.com/highlight/detail?id=2533856130","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533856130?lang=en_us&edition=fundamental","pubTime":"2025-05-06 05:41","pubTimestamp":1746481260,"startTime":"0","endTime":"0","summary":"Health-care companies ticked down amid mixed fortunes for the sector.BioCryst Pharmaceuticals shares surged after the biotech firm said it would turn a profit in 2025, a year earlier than anticipated, amid robust demand for Oraldeyo, a treatment for rare disease hereditary angioedema.BioNTech, the German biotech firm that rose to fame when it partnered with Pfizer on a Covid 19 vaccine, logged a hefty first-quarter loss and said it would focus on promising oncology programs from now on, citing risks to its current franchise from public policy and opinion.Henry Schein's first-quarter net income rose and the company backed its 2025 adjusted earnings projection as increased doctor-office visits buoyed medical sales, offsetting weakness in demand for dental-supply sales and the impact of a strong dollar.Health insurer UnitedHealth Group said it now has a thousand artificial-intelligence applications in production.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0456855351.SGD","LU0306807586.USD","LU1066051498.USD","LU0985481810.HKD","SG9999011175.SGD","IE00BLSP4452.SGD","BK4585","BK4599","LU1894683264.USD","LU1057294990.SGD","SG9999001176.USD","SGXZ57979304.SGD","IE00BBT3K403.USD","LU1894683348.USD","BK4581","BK4533","BK4534","BK4588","LU0306806265.USD","IE00B19Z3B42.SGD","LU1883839398.USD","SG9999001176.SGD","BK4007","LU0225284248.USD","LU0868494617.USD","IE00B19Z3581.USD","SG9999013999.USD","IE000M9KFDE8.USD","BK4550","IE00BLSP4239.USD","IE0002270589.USD","LU0225771236.USD","LU1066053197.SGD","LU0321505439.SGD","LU0234572021.USD","SG9999002224.SGD","LU0170899867.USD","LU0289739699.SGD","BK4568","SG9999003800.SGD","LU1023059063.AUD","LU0122379950.USD","BK4592","SG9999002232.USD","LU0321505868.SGD","LU0058720904.USD"],"gpt_icon":1},{"id":"2533576563","title":"Press Release: Viatris Announces Appointments of Frank D'Amelio and Michael Severino, M.D., to the Company's Board of Directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2533576563","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533576563?lang=en_us&edition=fundamental","pubTime":"2025-05-06 04:30","pubTimestamp":1746477000,"startTime":"0","endTime":"0","summary":"Viatris Announces Appointments of Frank D'Amelio and Michael Severino, M.D., to the Company's Board of Directors. Directors Rajiv Malik and Harry Korman to Retire at the End of Their Current Terms. PITTSBURGH, May 5, 2025 /PRNewswire/ -- Viatris Inc. , a global healthcare company, today announced that as part of its ongoing Board refreshment efforts, Frank D'Amelio and Michael Severino, M.D., have been appointed as the newest members of Viatris' Board of Directors. In addition, the Company announced that current directors, Rajiv Malik and Harry  Korman, will retire from the Board at the end of their current terms in December following the Company's 2025 Annual Meeting of Shareholders.Severino serves on the Board of Directors of Avantor, Inc., Montai Therapeutics, Inc., and Quotient Therapeutics, Inc. He earned an M.D. from Johns Hopkins University, completing his residency and fellowship training at Massachusetts General Hospital and Harvard Medical School, as well as a bachelor's degr","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BLSP4452.SGD","BK4599","LU0122379950.USD","IE00BBT3K403.USD","LU0306807586.USD","BK4585","LU0234572021.USD","BK4592","LU0321505868.SGD","VTRS","LU0985481810.HKD","SG9999002232.USD","LU0170899867.USD","IE00B19Z3B42.SGD","LU1883839398.USD","SG9999011175.SGD","LU0456855351.SGD","LU1023059063.AUD","BK4588","LU0868494617.USD","SG9999001176.SGD","LU1839511570.USD","IE000M9KFDE8.USD","BK4581","IE00B19Z3581.USD","LU0225771236.USD","BK4533","BK4568","IE0002270589.USD","LU1057294990.SGD","BK4550","LU1894683264.USD","BK4534","LU2087621335.USD","SG9999002224.SGD","SG9999013999.USD","IE00BLSP4239.USD","BK4583","LU1066053197.SGD","LU0321505439.SGD","LU0289739699.SGD","LU1894683348.USD","SG9999001176.USD","SGXZ57979304.SGD","SG9999003800.SGD","BK4007","LU0306806265.USD","LU1066051498.USD","LU0225284248.USD"],"gpt_icon":1},{"id":"2533573305","title":"BioNTech Appoints Novartis Executive As Finance Chief, Reaffirms 2025 Outlook Focusing on Oncology Expansion","url":"https://stock-news.laohu8.com/highlight/detail?id=2533573305","media":"Benzinga","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533573305?lang=en_us&edition=fundamental","pubTime":"2025-05-06 03:49","pubTimestamp":1746474564,"startTime":"0","endTime":"0","summary":"BioNTech&#39;s Q1 revenue hit $192 million, beating estimates; company confirms 2025 outlook and names new CFO ahead of oncology-focused expansion.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/25/05/45205736/biontech-appoints-novartis-executive-as-finance-chief-reaffirms-2025-guidance-focuses-on-oncology-expansion","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B19Z3B42.SGD","IE00BJJMRZ35.SGD","IE00B4R5TH58.HKD","BK4585","LU0289739699.SGD","BK4533","IE00BLSP4452.SGD","LU0234572021.USD","LU0170899867.USD","BK4550","LU1883839398.USD","IE000M9KFDE8.USD","IE00BJT1NW94.SGD","BK4548","LU0456855351.SGD","SG9999011175.SGD","BK4551","BNTX","LU1066053197.SGD","BK4139","LU0306806265.USD","BK4532","SG9999002232.USD","IE00B2B36J28.USD","LU0208291251.USD","LU1023059063.AUD","LU1057294990.SGD","BK4534","BK4592","IE00BFTCPJ56.SGD","LU0225771236.USD","SG9999003800.SGD","LU0225284248.USD","SG9999001176.SGD","LU0058720904.USD","LU1894683348.USD","LU0306807586.USD","BK4007","LU0321505439.SGD","SG9999013999.USD","SG9999002224.SGD","BK4535","BK4568","IE0002270589.USD","LU0868494617.USD","IE0002141913.USD","BK4578","LU1894683264.USD","NVS"],"gpt_icon":1},{"id":"2533551210","title":"Optimism is Back for Biotech Stocks. This Time, It Could Last. -- Barrons.com","url":"https://stock-news.laohu8.com/highlight/detail?id=2533551210","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533551210?lang=en_us&edition=fundamental","pubTime":"2025-05-06 02:49","pubTimestamp":1746470940,"startTime":"0","endTime":"0","summary":"Something strange has been happening with biotech stocks over the past few weeks: They have been going up.The SPDR S&P Biotech ETF, a benchmark for the sector, closed April 8 at $69.80, its worst closing price since November 2023. It was up 20% from that low by the end of the day on Friday, outperforming the S&P 500, which was up 14%. It had trounced the Health Care Select Sector SPDR ETF, which follows healthcare stocks writ large and was up 4.2%.The hope now is that the recent run-up, which began as the overall market surged after President Donald Trump delayed most of his promised tariffs by 90 days on April 9, is the first taste of a broader biotech recovery. The fear is that it is just a brief respite, driven by events outside the sector, from a selloff that will inevitably continue.Still, taking out the trash probably isn't enough to resurrect the sector. What biotech needs is to make some money, and these days that mostly means big pharma pulling out a checkbook and writing","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE000M9KFDE8.USD","LU1066051498.USD","IE00BLSP4452.SGD","BK4592","LU0170899867.USD","SG9999003800.SGD","SG9999001176.SGD","LU1057294990.SGD","SDS","LU1894683348.USD","LU0058720904.USD","BK4559","IE00BLSP4239.USD","SSO","BK4599","IE0002270589.USD","OP.USD.HKCC","SPY","LU1066053197.SGD","LU0306807586.USD","OEF","SG9999011175.SGD","BK4533","BK4550","PFE","SG9999013999.USD","BK4007","BK4504","LU1894683264.USD","VOO",".SPX","ESmain","SPXU","BK4534","THRD","LU0289739699.SGD","LU0868494617.USD","OEX","LU0321505439.SGD","LU0985481810.HKD","LU0321505868.SGD","BK4585","IVV","SH","LU0225771236.USD","BK4588","FDN","BK4568","SG9999002232.USD"],"gpt_icon":1},{"id":"2533559306","title":"BioNTech price target lowered to $127 from $143 at BofA","url":"https://stock-news.laohu8.com/highlight/detail?id=2533559306","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533559306?lang=en_us&edition=fundamental","pubTime":"2025-05-06 02:10","pubTimestamp":1746468634,"startTime":"0","endTime":"0","summary":"BofA analyst Tazeen Ahmad lowered the firm’s price target on BioNTech (BNTX) to $127 from $143 and keeps a Buy rating on the shares. The firm notes...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/biontech-price-target-lowered-to-127-from-143-at-bofa?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/biontech-price-target-lowered-to-127-from-143-at-bofa?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BNTX","BK4568","BK4585","BK4551","BK4548","BK4535","BK4588","BK4139"],"gpt_icon":0},{"id":"2533947556","title":"Sector Update: Health Care Stocks Lower Monday Afternoon","url":"https://stock-news.laohu8.com/highlight/detail?id=2533947556","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533947556?lang=en_us&edition=fundamental","pubTime":"2025-05-06 02:03","pubTimestamp":1746468181,"startTime":"0","endTime":"0","summary":"Health care stocks fell Monday afternoon, with the NYSE Health Care Index down 0.2% and the Health Care Select Sector SPDR Fund  decreasing 0.1%.The iShares Biotechnology ETF  shed 0.3%.In corporate news, BioNTech  shares dropped 2.7% after the company reported an unexpected decline in Q1 sales.Capricor Therapeutics  shares tumbled past 10% after the company said the US Food and Drug Administration plans to hold an advisory committee meeting to review its biologics license application for deramiocel, an investigational cell therapy for treating cardiomyopathy in Duchenne muscular dystrophy patients.Rezolute  shares popped 2.9% after the company said the FDA granted breakthrough therapy designation for ersodetug, an investigational treatment for hypoglycemia caused by tumor hyperinsulinism.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4568","BNTX","BK4535","CAPR","XLV","BK4548","IBB","RZLT","BK4585","BK4581","BK4551","BK4588","BK4139"],"gpt_icon":0},{"id":"2533336559","title":"Analysts Offer Insights on Healthcare Companies: BioNTech SE (BNTX), PTC Therapeutics (PTCT) and Larimar Therapeutics (LRMR)","url":"https://stock-news.laohu8.com/highlight/detail?id=2533336559","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533336559?lang=en_us&edition=fundamental","pubTime":"2025-05-06 01:50","pubTimestamp":1746467408,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on BioNTech SE (BNTX – Research Report), PTC Therapeuti...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-biontech-se-bntx-ptc-therapeutics-ptct-and-larimar-therapeutics-lrmr?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-biontech-se-bntx-ptc-therapeutics-ptct-and-larimar-therapeutics-lrmr?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU2506952410.USD","BNTX","LU0109394709.USD","LU2362540622.SGD","BK4576","BK4551","BK4585","BK4139","LU1951200564.SGD","BK4535","BK4588","LU2477742899.HKD","BK4568","LU0320765992.SGD","BK4023","LRMR","LU2362541273.HKD","LU1721428347.USD","LU1951198990.SGD","LU2362541513.USD","BK4137","HCSG","PTC","PTCT","LU0889565916.HKD","LU1923623000.USD","BK4554","LU2506952337.HKD","BK4548"],"gpt_icon":0},{"id":"2533396715","title":"Narrower Guidelines for Covid-19 Booster Wouldn't Limit BioNTech's Customer Base Much -- Market Talk","url":"https://stock-news.laohu8.com/highlight/detail?id=2533396715","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533396715?lang=en_us&edition=fundamental","pubTime":"2025-05-05 23:13","pubTimestamp":1746457980,"startTime":"0","endTime":"0","summary":"1112 ET - BioNTech expects its Covid-19 booster sales to stay relatively stable even if the government narrows its recommendations of who needs the shot. The Centers for Disease Control is scheduled to vote in June on a new recommendation for who should get the Covid-19 booster, which could narrow it to high-risk groups only. BioNTech, which rose to prominence for its partnership with Pfizer during the Covid-19 pandemic, says during an analyst call that many of the people still getting the booster are in high-risk groups already. The majority of Covid vaccines in the U.S. are going to people who are older than 65 or immunocompromised, which accounts for about 20% of Americans, management says. ","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0306806265.USD","IE0002270589.USD","IE000M9KFDE8.USD","BK4533","LU0456855351.SGD","LU1066051498.USD","BK4581","LU1023059063.AUD","IE00BLSP4452.SGD","LU0321505868.SGD","BK4007","IE00BBT3K403.USD","LU1057294990.SGD","LU0321505439.SGD","IE00B19Z3B42.SGD","LU1066053197.SGD","BK4550","BNTX","IE00B19Z3581.USD","LU0225771236.USD","BK4585","SG9999013999.USD","LU0868494617.USD","BK4588","LU1894683348.USD","LU1894683264.USD","SG9999002224.SGD","BK4534","BK4568","IE00BLSP4239.USD","LU0225284248.USD","LU1883839398.USD","BK4599","LU0985481810.HKD","SG9999003800.SGD","LU0170899867.USD","SG9999011175.SGD","LU0234572021.USD","BK4592","LU0058720904.USD","LU0289739699.SGD","SGXZ57979304.SGD","SG9999002232.USD","LU0122379950.USD","SG9999001176.USD","LU0306807586.USD","SG9999001176.SGD"],"gpt_icon":1},{"id":"2533539125","title":"European Equities Traded in the US as American Depositary Receipts Marginally Higher in Monday Trading","url":"https://stock-news.laohu8.com/highlight/detail?id=2533539125","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533539125?lang=en_us&edition=fundamental","pubTime":"2025-05-05 23:12","pubTimestamp":1746457927,"startTime":"0","endTime":"0","summary":"European equities traded in the US as American depositary receipts were marginally higher late Monday morning, rising 0.06% to 1,423.70 on the S&P Europe Select ADR Index.From continental Europe, the ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0162691827.USD","CLLS","BK4546","BK4023","BK4107","BK4082","SLN","BK4588","BK4207","BK4007","LU1829250122.USD","BNTX","TRIB","BK4535","BK4505","BK4568","BCYC","ADAP","MTLS","BK4139","LU0320765646.SGD","BK4585","LU1162221912.USD","BP","DBVT","BK4201","E","EDAP","BK4548","AFG","NCNA","GNFT","AKTX","MREO","BBVA","BK4551","LU0072461881.USD","BK4117"],"gpt_icon":0},{"id":"2533368765","title":"India Offers US Reciprocal Zero Tariffs on Steel, Auto Parts, Pharmaceutical Drugs, Bloomberg Reports","url":"https://stock-news.laohu8.com/highlight/detail?id=2533368765","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533368765?lang=en_us&edition=fundamental","pubTime":"2025-05-05 22:48","pubTimestamp":1746456505,"startTime":"0","endTime":"0","summary":"Price: 42.97, Change: -1.08, Percent Change: -2.45","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4588","LU0820561818.USD","BK4547","IE00BLSP4452.SGD","BK4568","LU0097036916.USD","NVS","TSYW.SI","LU1435385759.SGD","LU2756315318.SGD","LU0345769631.USD","LU1551013425.SGD","LU1861220033.SGD","LU2108987350.USD","LU1064927863.SGD","LU0082616367.USD","LU1232071149.USD","BK4578","BK4559","LU0348723411.USD","X","LU2456880835.USD","HMC","LU0321505868.SGD","BK4533","LU2290526834.HKD","LU0466842654.USD","LU0130517989.USD","LU0130103400.USD","IE00BJJMRZ35.SGD","AZN","LU1066051811.HKD","GM","STLA","F","LU0820562030.AUD","GSK.UK","LU1201861249.SGD","GSK","LU2471134523.USD","03160","IE0034235303.USD","LU0162691827.USD","LU0323591593.USD","LU2213496289.HKD","TM"],"gpt_icon":0},{"id":"2533539742","title":"Why Gilead Sciences (GILD) is a Top Value Stock for the Long-Term","url":"https://stock-news.laohu8.com/highlight/detail?id=2533539742","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533539742?lang=en_us&edition=fundamental","pubTime":"2025-05-05 21:40","pubTimestamp":1746452409,"startTime":"0","endTime":"0","summary":"It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors.While you may have an investing style you rely on, finding great stocks is made easier with the Zacks Style Scores. These are complementary indicators that rate stocks based on value, growth, and/or momentum characteristics.Why Investors Should Pay Attention to This Value Stock. Value investors love finding good stocks at good prices, especially before the broader market catches on to a stock's true value. Utilizing ratios like P/E, PEG, Price/Sales, and Price/Cash Flow, the Value Style Score identifies the most attractive and most discounted stocks.GILD is a Zacks Rank #3  stock, with a Value Style Score of B and VGM Score of A. Shares are currently trading at a forward P/E of 13.1X for the current fiscal year compared to the Medical - Biomedical and Genetics industry's P/E of 17.8X. Additionally, GILD has a PEG Ratio of 0.7 and a Price/C","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/why-gilead-sciences-gild-top-134009528.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU1430594728.SGD","LU1066053197.SGD","LU1585245621.USD","LU1571399168.USD","BK4568","IE00B19Z3B42.SGD","IE00BSNM7G36.USD","LU0234570918.USD","BK4139","LU1066051498.USD","BK4585","LU0109394709.USD","LU0320765992.SGD","LU2087621335.USD","BK4588","IE00BZ1G4Q59.USD","IE00B7SZLL34.SGD","GILD","IE00BKVL7J92.USD","LU2468319806.SGD","LU0289739699.SGD","BK4578","IE00B19Z3581.USD","IE0002270589.USD","BK4566","BK4583","IE00B3T34201.USD","LU2089984988.USD","LU0058720904.USD","BK4550","LU1839511570.USD","LU0889565916.HKD","BK4532"],"gpt_icon":0},{"id":"2533638582","title":"BRIEF-Novavax To Receive $19.5 Million Upfront Payment Under Amended Agreement With Takeda","url":"https://stock-news.laohu8.com/highlight/detail?id=2533638582","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533638582?lang=en_us&edition=fundamental","pubTime":"2025-05-05 21:27","pubTimestamp":1746451679,"startTime":"0","endTime":"0","summary":"BRIEF-Novavax To Receive $19.5 Million Upfront Payment Under Amended Agreement With Takeda May 5 (Reuters) - Novavax:NOVAVAX - TO RECEIVE $19.5 MILLION UPFRONT PAYMENT UNDER AMENDED AGREEMENT WITH TAKEDA - SEC FILINGSource text: [ID:n0001104659-25-044372] ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250505:nFWN3RD20T:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4547","NVAX","BK4588","BK4139","BK4568","BK4585"],"gpt_icon":0},{"id":"2533582635","title":"Novavax - to Receive $19.5 Mln Upfront Payment Under Amended Agreement With Takeda - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2533582635","media":"THOMSON REUTERS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533582635?lang=en_us&edition=fundamental","pubTime":"2025-05-05 21:27","pubTimestamp":1746451634,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250505:nFWN3RD20T:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4547","BK4139","BK4568","BK4588","NVAX","BK4585"],"gpt_icon":0},{"id":"2533848275","title":"Johnson & Johnson Says New Data Show Tremfya's Sustained Efficacy in Ulcerative Colitis","url":"https://stock-news.laohu8.com/highlight/detail?id=2533848275","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533848275?lang=en_us&edition=fundamental","pubTime":"2025-05-05 20:59","pubTimestamp":1746449961,"startTime":"0","endTime":"0","summary":"Johnson & Johnson  said Monday that new data from a phase 3 study of Tremfya, or guselkumab, showed its sustained clinical and endoscopic efficacy through week 92 in adults with moderately to severely active ulcerative colitis.The company said 72% of patients treated with Tremfya were in clinical remission, with nearly all of them staying off steroid treatment for two months or longer, and 43% achieved endoscopic remission.Among those who improved by week 44, 84% retained that progress through week 92, Johnson & Johnson said.The outcomes were consistent regardless of prior exposure to biologic drugs or JAK inhibitors, according to the company.No new safety issues were identified, and the drug's risk profile remained consistent with previous findings, the company said.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU2592432038.USD","LU1674673691.USD","LU1162221912.USD","LU0234572021.USD","LU1244550221.USD","LU1732799900.SGD","IE0002270589.USD","IE0034235303.USD","LU1914381329.SGD","LU2133065610.SGD","LU1585245621.USD","BK4568","LU1506573853.SGD","LU0795875086.SGD","LU1280957306.USD","LU2468319806.SGD","BK4592","LU1894683348.USD","JNJ","LU1032466523.USD","LU2089984988.USD","LU1196500208.SGD","IE0002141913.USD","IE00BVYPNW00.USD","LU1244550494.USD","LU0466842654.USD","LU1059921491.USD","LU1074936037.SGD","LU0795875169.SGD","LU2505996509.AUD","LU1261432733.SGD","LU2129689514.USD","LU2602419157.SGD","LU0122379950.USD","LU1929549753.HKD","IE00BJT1NW94.SGD","BK4504","IE0009355771.USD","IE00BSNM7G36.USD","IE00B19Z3581.USD","IE00BN8TJ469.HKD","BK4588","SG9999002232.USD","LU0345769631.USD","BK4532","SG9999001440.SGD","BK4533","LU0114720955.EUR","LU0345769128.USD","IE00B19Z3B42.SGD"],"gpt_icon":0},{"id":"2533171581","title":"Novavax Updates Financial Terms With Takeda for Covid-19 Vaccine Agreement in Japan","url":"https://stock-news.laohu8.com/highlight/detail?id=2533171581","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533171581?lang=en_us&edition=fundamental","pubTime":"2025-05-05 20:50","pubTimestamp":1746449456,"startTime":"0","endTime":"0","summary":"Novavax  said Monday it updated financial terms of an agreement with Takeda  for the development and commercialization of its Covid-19 vaccine, Nuvaxovid, in Japan.The company said the improved financial terms of the amended deal include an upfront payment, compensation tied to the 2024/2025 season, annual milestone payments linked to regulatory approvals, and royalties on seasonal net sales going forward.NVAX shares were 1.1% higher in recent premarket activity.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4568","BK4139","NVAX","BK4551","BK4588","BK4007","BK4548","BNTX","BK4547","BK4585","BK4535","TAK"],"gpt_icon":0},{"id":"2533589301","title":"BRIEF-Novavax Announces Improved Terms For Collaboration, License Agreement With Takeda For Nuvaxovid In Japan","url":"https://stock-news.laohu8.com/highlight/detail?id=2533589301","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533589301?lang=en_us&edition=fundamental","pubTime":"2025-05-05 20:28","pubTimestamp":1746448113,"startTime":"0","endTime":"0","summary":"BRIEF-Novavax Announces Improved Terms For Collaboration, License Agreement With Takeda For Nuvaxovid In JapanMay 5 (Reuters) - Novavax Inc NVAX.O:NOVAVAX ANNOUNCES SIGNIFICANTLY IMPROVED TERMS FOR CO","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250505:nTUABYWNX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4547","BK4139","BK4568","BK4588","NVAX"],"gpt_icon":0}],"pageSize":20,"totalPage":17,"pageCount":5,"totalSize":328,"code":"91000000","status":"200"}]}}